EP3316883A4 - Inhibitoren des fkbp51-proteins aus einem hochdurchsatz-arzneimittelscreening und verfahren zur verwendung davon - Google Patents

Inhibitoren des fkbp51-proteins aus einem hochdurchsatz-arzneimittelscreening und verfahren zur verwendung davon Download PDF

Info

Publication number
EP3316883A4
EP3316883A4 EP15897348.7A EP15897348A EP3316883A4 EP 3316883 A4 EP3316883 A4 EP 3316883A4 EP 15897348 A EP15897348 A EP 15897348A EP 3316883 A4 EP3316883 A4 EP 3316883A4
Authority
EP
European Patent Office
Prior art keywords
medicines
inhibitors
screening
methods
high yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15897348.7A
Other languages
English (en)
French (fr)
Other versions
EP3316883A1 (de
Inventor
Jonathan Jacob Sabbagh
Chad Dickey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Publication of EP3316883A1 publication Critical patent/EP3316883A1/de
Publication of EP3316883A4 publication Critical patent/EP3316883A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15897348.7A 2015-06-30 2015-06-30 Inhibitoren des fkbp51-proteins aus einem hochdurchsatz-arzneimittelscreening und verfahren zur verwendung davon Withdrawn EP3316883A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/038664 WO2017003469A1 (en) 2015-06-30 2015-06-30 Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use

Publications (2)

Publication Number Publication Date
EP3316883A1 EP3316883A1 (de) 2018-05-09
EP3316883A4 true EP3316883A4 (de) 2019-06-12

Family

ID=57608833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15897348.7A Withdrawn EP3316883A4 (de) 2015-06-30 2015-06-30 Inhibitoren des fkbp51-proteins aus einem hochdurchsatz-arzneimittelscreening und verfahren zur verwendung davon

Country Status (2)

Country Link
EP (1) EP3316883A4 (de)
WO (1) WO2017003469A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051624B1 (ko) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091900A1 (en) * 2011-12-22 2013-06-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
WO2015039758A1 (en) * 2013-09-19 2015-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective fkbp51 ligands for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2011054399A1 (en) * 2009-11-06 2011-05-12 Avail Gmbh Improvement of the glucocorticoid receptor function in asthma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091900A1 (en) * 2011-12-22 2013-06-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
WO2015039758A1 (en) * 2013-09-19 2015-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective fkbp51 ligands for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
O'LEARY J ET AL: "FKBP5 gene deletion prevents susceptibility to depression", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 41, 2011, & 41ST ANNUAL MEETING OF THE SOCIETY-FOR-NEUROSCIENCE; WASHINGTON, DC, USA; NOVEMBER 12 -16, 2011, XP002787677 *
SCHMIDT MATHIAS V ET AL: "The Prospect of FKBP51 as a Drug Target", CHEMMEDCHEM, vol. 7, no. 8, August 2012 (2012-08-01), pages 1351 - 1359, ISSN: 1860-7179 *
See also references of WO2017003469A1 *
STRANG R R: "Experiences with cogentin in the treatment of Parkinsonism. A one-year controlled study of 94 patients.", ACTA NEUROLOGICA SCANDINAVICA 1966, vol. 41, no. 4, 1966, pages 413 - 418, XP002787676, ISSN: 0001-6314 *
TISLOW R F: "USEFULNESS OF ANTI CHOLINERGIC DRUGS IN SUPPRESSING SYMPTOMS OF DEPRESSION IN MAN ABSTRACT BENZTROPINE CENT STIM TRIHEXYPHENIDYL CENT STIM BIPERIDEN CENT STIM", FEDERATION PROCEEDINGS, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 28, no. 2, 1 January 1969 (1969-01-01), pages 728, XP009510075, ISSN: 0014-9446 *

Also Published As

Publication number Publication date
EP3316883A1 (de) 2018-05-09
WO2017003469A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3317213A4 (de) Vibrationssiebzuführer und verfahren zur verwendung
EP3295098A4 (de) Tragbarer kühlschrank und verfahren zur verwendung
DK3289362T3 (da) Detektering og sortering af mikrofluid-smådråber
EP3350314A4 (de) Oligonukleinsäurevariantenbibliotheken variante und synthese davon
EP3394065A4 (de) Tetrahydropyranyl-amino-pyrrolopyrimidinon und verfahren zur verwendung davon
EP3303435A4 (de) Hydrofluorolefine und verfahren zur verwendung davon
EP3445876C0 (de) Einzelzellenanalyse von transposasezugänglichem chromatin
EP3294165A4 (de) Verfahren zur implantation einer knochenschraube
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
EP3287744A4 (de) Routensuchvorrichtung und routensuchverfahren
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3368663A4 (de) Virusfreie zelllinien und verfahren zur herstellung davon
EP3426693A4 (de) Verfahren zur modularen synthese von n-glykanen und anordnungen davon
IL251136A0 (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3394098A4 (de) Anti-myostatin-antikörper und verfahren zur verwendung
EP3369192A4 (de) Detektion von ressourcenzugriff
EP3315233A4 (de) Kräuselungsverfahren mit schaftfräser sowie schaftfräser
EP3331563A4 (de) Anti-cd154-antikörper und verfahren zur verwendung davon
EP3314686A4 (de) Kathode mit nanoskaliger porenstruktur für hochleistungsanwendungen und materialsyntheseverfahren
EP3373005A4 (de) Reagens und verfahren für test auf kardiales troponin-i
EP3458448A4 (de) Verfahren zur verwendung von fasn-hemmern
EP3319682A4 (de) Ventilanordnung und verfahren zur verwendung
EP3313865A4 (de) Synthetische peptidverbindungen und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DICKEY, CHAD

Inventor name: SABBAGH, JONATHAN JACOB

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101ALI20190114BHEP

Ipc: A61K 31/498 20060101ALI20190114BHEP

Ipc: A61P 25/28 20060101ALI20190114BHEP

Ipc: A61K 31/415 20060101ALI20190114BHEP

Ipc: A61K 31/439 20060101AFI20190114BHEP

Ipc: A61P 25/00 20060101ALI20190114BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190514

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/498 20060101ALI20190508BHEP

Ipc: A61K 31/415 20060101ALI20190508BHEP

Ipc: A61K 31/439 20060101AFI20190508BHEP

Ipc: A61P 25/00 20060101ALI20190508BHEP

Ipc: A61K 31/445 20060101ALI20190508BHEP

Ipc: A61P 25/28 20060101ALI20190508BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201223